Author(s)
Ania Wajnberg
Published 4 Projects
COVID-19 SARS-CoV-2 Infectious Diseases Key Words Convalescent Plasma
Damodara Rao Mendu
Published 5 Projects
COVID-19 SARS-CoV-2 Infectious Diseases Key Words Convalescent Plasma
Adolfo Firpo-Betancourt
Published 2 Projects
COVID-19 SARS-CoV-2 Infectious Diseases Key Words Convalescent Plasma
Carlos Cordon-Cardo
Published 5 Projects
COVID-19 SARS-CoV-2 Infectious Diseases Key Words Convalescent Plasma
Content
Video Abstract (AI generated) (00:10) Paper PreprintBackground Since December 2019, Coronavirus Disease 2019 (COVID-19) has become a global pandemic, causing mass morbidity and mortality. Prior studies in other respiratory infections suggest that convalescent plasma transfusion may offer benefit to some patients. Here, the outcomes of thirty-nine hospitalized patients with severe to life-threatening COVID-19 who received convalescent plasma transfusion were compared against a cohort of retrospectively matched controls. Methods Plasma recipients were selected based on supplemental oxygen needs at the time of enrollment and the time elapsed since the onset of symptoms. Recipients were transfused with convalescent plasma from donors with a SARS-CoV-2 (severe acute respiratory disease coronavirus 2) anti-spike antibody titer of [≥]1:320 dilution. Matched control patients were retrospectively identified within the electronic health record database. Supplemental oxygen requirements and survival were compared between plasma recipients and controls. Results Convalescent plasma recipients were more likely than control patients to remain the same or have improvements in their supplemental oxygen requirements by post-transfusion day 14, with an odds ratio of 0.86 (95% CI: 0.75~0.98; p=0.028). Plasma recipients also demonstrated improved survival, compared to control patients (log-rank test: p=0.039). In a covariates-adjusted Cox model, convalescent plasma transfusion improved survival for non-intubated patients (hazard ratio 0.19 (95% CI: 0.05 ~0.72); p=0.015), but not for intubated patients (1.24 (0.33~4.67); p=0.752). Conclusions Convalescent plasma transfusion is a potentially efficacious treatment option for patients hospitalized with COVID-19; however, these data suggest that non-intubated patients may benefit more than those requiring mechanical ventilation.
More Projects
Loren Frank
13 views • 2 years ago
Global Immunotalks
390 views • 3 years ago
Laurel Yohe
2 views • 2 years ago
Global Immunotalks
130 views • 3 years ago
Jignesh H. Parmar
0 views • 2 years ago
Winston A. Haynes
0 views • 2 years ago
Noam Mazor
0 views • 2 years ago
Global Immunotalks
182 views • 3 years ago
Cem Yuksel
345 views • 3 years ago
Oscar Gonzalez-Recio
3 views • 2 years ago
Please pick a style:
Florian Krammer. (2021, Oct 30).Convalescent plasma treatment of severe COVID-19: A matched control study[Video]. Scitok. https://scitok.com/project/p/aca56193
T.H. Liu Sean. "Convalescent plasma treatment of severe COVID-19: A matched control study" Scitok, uploaded by Krammer Florian, 30 Oct, 2021, https://scitok.com/project/paca56193
Florian Krammer. "Convalescent plasma treatment of severe COVID-19: A matched control study" Scitok. (Oct 30, 2021). https://scitok.com/project/p/aca56193
Florian Krammer (Oct 30, 2021). Convalescent plasma treatment of severe COVID-19: A matched control study Scitok. https://scitok.com/project/p/aca56193
Florian Krammer. Convalescent plasma treatment of severe COVID-19: A matched control study[video]. 2021 Oct 30. https://scitok.com/project/p/aca56193
@online{al2006link, title={ Convalescent plasma treatment of severe COVID-19: A matched control study }, author={ Krammer, Florian }, organization={Scitok}, month={ Oct }, day={ 30 }, year={ 2021 }, url = {https://scitok.com/project/p/aca56193}, }